

# Orthopaedic Nursing

## Development and testing of a new instrument for measuring quality of life in osteoporosis after a non-vertebral fracture: The Quality of Life Osteoporosis Scale—Non-vertebral Fractures (QoLOS-NVFX)

--Manuscript Draft--

<b>Manuscript Number:</b>	
<b>Full Title:</b>	Development and testing of a new instrument for measuring quality of life in osteoporosis after a non-vertebral fracture: The Quality of Life Osteoporosis Scale—Non-vertebral Fractures (QoLOS-NVFX)
<b>Article Type:</b>	Original Manuscript
<b>Keywords:</b>	QoL; NVFX; Postmenopausal osteoporosis; Scale
<b>Corresponding Author:</b>	Emanuela Basilici Zannetti, PhD, RN Rome, Rome ITALY
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Emanuela Basilici Zannetti, PhD, RN
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Emanuela Basilici Zannetti, PhD, RN Daniela D'angelo, PhD, RN Noemi Cittadini, PhD, RN Monica Celi, MD Annalisa Pennini, PhD, RN Gennaro Rocco, PhD, RN Ercole Vellone, PhD, RN, FESC Rosaria Alvaro, MSN, RN, FESC Umberto Tarantino, PhD, MD
<b>Order of Authors Secondary Information:</b>	

**Development and testing of a new instrument for measuring quality of life in osteoporosis after a non-vertebral fracture: The Quality of Life Osteoporosis Scale—Non-vertebral Fractures (QoLOS-NVFX)**

Emanuela BASILICI ZANNETTI, PhD, RN  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Daniela D'ANGELO, PhD, RN  
Research fellow  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Noemi CITTADINI, PhD, RN  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Monica CELI, MD  
PhD student in Orthopaedic Surgeons  
Department of Orthopaedics and Traumatology, University of Rome Tor Vergata  
Rome, Italy

Annalisa PENNINI, PhD, RN  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Gennaro ROCCO, PhD, RN  
Research fellow  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Ercole VELLONE, PhD, RN, FESC  
Assistant professor  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Rosaria ALVARO, MSN, RN, FESC  
Full Professor  
Department of Biomedicine and Prevention, University of Rome Tor Vergata  
Rome, Italy

Umberto TARANTINO, PhD, MD  
Full Professor  
Department of Orthopaedics and Traumatology Policlinico Tor Vergata Foundation, University of Rome Tor Vergata  
Rome, Italy

Address for Correspondence

Daniela D'ANGELO

Research fellow

Department of Biomedicine and Prevention, University of Rome Tor Vergata

Rome, Italy

Via Montpellier, 1

00133 Rome, Italy

email: d.angelo@med.uniroma2.it; phone: + 39 3927828323; fax: + 39 0672596961

**Acknowledgements.** This study was funded by the Center of Excellence for Nursing Scholarship, Rome, Italy.

**Conflict of Interest**

Emanuela Basilici Zannetti, Daniela D'angelo, Noemi Cittadini, Monica Celi, Annalisa Pennini, Gennaro Rocco, Ercole Vellone, Rosaria Alvaro, Umberto Tarantino declare that they have no conflict of interest.

**Development and testing of a new instrument for measuring quality of life in osteoporosis after a non-vertebral fracture: The Quality of Life Osteoporosis Scale—Non-vertebral Fractures (QoLOS-NVFX)**

**Abstract**

*Purpose* The aim of this study was developing and testing a new tool for measuring quality of life (QoL) in patients with osteoporosis who had experienced non-vertebral fractures (NVFX).

*Methods* Two main phases were carried out. Firstly, the tool was developed based on expert opinions through three focus groups. Secondly, the tool was tested with exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) in a sample of 458 postmenopausal women. The reliability of the developed QoL Osteoporosis Scale—NVFX (QoLOS-NVFX) was measured using Cronbach's alpha ( $\alpha$ ), maximal reliability (MR), composite reliability (CR), and average variance extracted (AVE).

*Results* The QoLOS-NVFX resulted in a unidimensional scale with 23 items and showed good reliability, with a Cronbach's  $\alpha$  of .94, MR of .96, CR of .96, and AVE of .70.

*Conclusions* The QoLOS-NVFX shows good psychometric properties and can be used to assess the impact of NVFX on QoL in osteoporotic women. Furthermore, it can be easily used in clinical practice and research.

## Introduction

Osteoporosis is defined as a systematic skeletal disorder characterized by low bone mass and microarchitectural deterioration of the bone tissue, with a consequent increase in bone fragility (Lin et al., 2015). The prevalence of osteoporosis is approximately 6% in men and 21% in women aged 50–84 years. Since women have more severe bone loss and experience falls more frequently than men do, the prevalence of osteoporosis in women over the age of 50 years is 3–4 times greater than that in men. The prevalence of osteoporosis in the European Union was estimated as 27.6 million people in 2010 (Hernlund et al., 2013).

The most important consequences of osteoporosis are fragility fractures, which can be divided into vertebral fractures (VFX) and non-vertebral fractures (NVFX) (Wilson, Sharp, & Davie, 2012). Among the fragility fractures, while VFX represent only 14.85%, NVFX make up 85.15% of all fractures (*Broken Bones, Broken Lives*, n.d.). Although VFX are the main cause of morbidity and mortality, NVFX are equally important. These fractures include, most frequently, fractures of the hip, forearm and humerus (Tsuda, 2017), rib, tibia, pelvis, and femur (Pisani et al., 2016), and they have an important influence on the quality of life (QoL) of osteoporotic patients. In fact, NVFX also cause losses of physical functioning for patients and reduce their mobility and self-care. For example, half the patients who can walk before an NVFX need a mobility aid for the rest of their lives or lose their independent walking ability afterwards (Pisani et al., 2016); up to one-third of people who experience a hip fracture become totally dependent (Panula et al., 2011); the 15–20% of osteoporotic patients with femoral fracture experience a reduction in their life expectancy by 4% per year (Edelmuth, Sorio, Sprovieri, Gali, & Peron, 2018); and finally, NVFX are associated with important decreases in physical and mental QoL (“The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization..” 1995; Yilmaz, Doğu, Sahin, Sirzai, & Kuran, 2014).

Considering that all fractures affect osteoporosis patients’ QoL enormously, investigators have developed several instruments for measuring QoL in this specific population. However, while several investigators have developed a number of instruments to measure QoL for VFX [11–25], far fewer have developed instruments to measure QoL in patients with NVFX. In fact, to our knowledge, only one instrument has been developed for NVFX, specifically for wrist fracture. This instrument, called the International Osteoporosis Foundation—Wrist Fracture Questionnaire (Lips et al., 2010), measures QoL considering pain, upper limb symptoms (wrist or forearm), physical function, and general health, but it cannot be used for other NVFX, such as the hip and femur, as it does not consider lower limb fractures; furthermore, it does not assess individuals’ emotional states or even all the

1 abilities to perform specific activities of daily life (ADL). Considering this, the aim of this study was  
2 to develop and test a new tool for measuring QoL in patients with osteoporosis who had experienced  
3 an NVFX.  
4  
5  
6

## 7 **Methods**

8  
9  
10 The QoLOS-NVFX was developed in the phases described below.

### 11 *Phase I: Scale development*

12  
13  
14 The item development first included a literature review to search for existing instruments  
15 measuring QoL in osteoporosis patients with fragility fractures. Afterward, three focus groups were  
16 organized with the aim of developing QoLOS-NVFX items. After the focus group meetings, the  
17 QoLOS-NVFX comprised 23 items. The responses to each IT were developed with a 3-point Likert  
18 scale format with the following options: insufficient (score 1), good (2), and excellent (3) or never  
19 (1), sometimes (2), and every day (3). With this response format, a higher score indicates better QoL.  
20 The total score of the QoLOS-NVFX ranged between 23 and 69, with higher scores meaning better  
21 QoL, as for each single IT. A list of the QoLOS-NVFX items is reported in Table 2.  
22  
23  
24  
25  
26  
27  
28  
29

### 30 *Phase II: Psychometric testing*

31  
32 QoLOS-NVFX psychometric testing was performed in a cross-sectional multicenter  
33 validation study. The study was conducted in outpatient clinics of several healthcare institutions  
34 throughout Italy, including 1 in the north, 11 in the center, and 13 in the south. The data collection  
35 was performed between January 2013 and December 2016 in two cohorts of patients: the first cohort  
36 included 195 women enrolled in 2013 and 2014, while the second cohort included 263 women  
37 enrolled in 2015 and 2016.  
38  
39  
40  
41  
42

43 The patients were recruited for the study if they met the following inclusion criteria: women  
44 in menopause, history of previous or current fracture other than vertebral fracture, willingness to  
45 participate in the study and sign the informed consent form, and ability to read and write Italian. The  
46 exclusion criteria were the presence of severe renal failure or pre-existing/ongoing neoplastic diseases  
47 and the presence of vertebral fractures. Nurses trained on the study protocol recruited the participants  
48 and administered the questionnaires. Each patient completed the self-reported questionnaire in a  
49 private room. Furthermore, women were asked to respond to the SF36 general question on their health  
50 status (Jenkinson, Coulter, & Wright, 1993).  
51  
52  
53  
54  
55  
56  
57  
58  
59

## 60 **Ethical Considerations**

1 The study was approved by the ethics committee of the Policlinico Tor Vergata of Rome in  
2 April 2013 (Prot. No. 0008650 of 17.04.2013). All the patients voluntarily agreed to participate in  
3 this study and gave their written consent. Before collecting their written consent, all the participants  
4 were fully informed by the research assistants that they could withdraw from the study at any time  
5 without giving a reason and their data would remain confidential.  
6  
7  
8  
9

## 10 11 **Statistical Analysis**

12  
13  
14 Descriptive statistics (e.g., mean and standard deviation [SD]) were used for describing the  
15 sociodemographic and clinical characteristics of the sample. Moreover, statistics (e.g., skewness and  
16 kurtosis) were also used for describing the QoLOS-NVFX items, as well as the frequency of the IT  
17 answer categories.  
18  
19  
20

21 The factorial structure of QoLOS-NVFX was tested with both exploratory factor analysis  
22 (EFA) and confirmatory factor analysis (CFA). Specifically, EFA was used on the first cohort of  
23 patients (195 women enrolled in 2013 and 2014; calibration sample), while CFA was used on the  
24 second cohort of patients (women enrolled in 2015 and 2016; validation sample) (Byrne, 2012). The  
25 EFA on the calibration sample was used for studying the factorial structure of the QoLOS-NVFX.  
26 With the EFA, we identified the final factor solution by scrutinizing the scree plot of eigenvalues and  
27 evaluating the interpretability of the solution (Brown, 2015). In this regard, when the scree plot  
28 suggests a substantial plateau, no other factors should be retained in the final solution after the first  
29 evident peak. In contrast, the CFA on the validation sample was used for replicating the factor  
30 structure identified in the EFA. Since the items were ordered categorically, weighted least squares  
31 means and variance-adjusted (WLSMV) estimators were used for the model estimation, both for the  
32 EFA and CFA (Muthén, L. K., & Muthén, n.d.), with the full-information maximum likelihood  
33 (FIML) used for handling missing data (Arbuckle, 1996). EFA was implemented using the oblique  
34 geomin rotation (Muthén, L. K., & Muthén, n.d.). Both EFA and CFA were assessed by adopting a  
35 multifaceted approach for fit evaluation, using the following indices and criteria: chi-square  
36 significance (if chi-square was not significant, the model reached a perfect fit with the observed data);  
37 root mean square error of approximation (RMSEA) (Steiger, 1990): values  $\leq .08$ , or better,  $\leq .05$   
38 indicate a good fit, as well as to not rejected of the null hypothesis (for  $p < .05$ ) associated with its  
39 90% confidence interval (CI) (Hu & Bentler, 1999); and comparative fit index (CFI) (Bentler, 1990)  
40 and Tucker–Lewis index (TLI) or non-normed fit index (Tucker & Lewis, 1973): values  $\geq .95$  indicate  
41 a good fit.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Convergent validity was assessed by means of polyserial correlations of the QoLOS-NVFX total scores with the overall health status question in both samples. The QoLOS-NVFX's reliability in the calibration sample was estimated with the nonlinear structural equation modeling (SEM) coefficient (NSC), a statistic for ordered categorical indicators (Green & Yang, 2009). The values for this coefficient are interpreted comparably to those of Cronbach's alpha ( $\alpha$ ) (Nunnally, J. C. and Bernstein, 1994). Since CFA in the confirmation sample was performed with IT parceling, and the NSC is not meaningful for testing reliability, the QoLOS-NVFX's reliability in the confirmation sample was computed with other estimates, as follows: Cronbach's alpha ( $\alpha$ ), maximal reliability (MR), composite reliability (CR), and average variance extracted (AVE). All these indices ranged from 0 to 1, with values closer to 1 suggesting a higher reliability of the overall scale. The analyses were carried out using SPSS 22.0 (IBM, 2013) and MPlus 7.1. (Muthén, L. K., & Muthén, n.d.).

## Results

### *Patient characteristics and scale scores*

The sample included 458 postmenopausal osteoporotic women with a mean age of 75 years (SD 58.18). Most (52.6%) had a low level of education and more than three-quarters (76.8%) were either unemployed or retired. Most of the participants had a normal weight or were slightly overweight, with a body mass index (BMI) ranging from 20 to 29.9.

The mean age of the women's menopause occurrence was 49 years and the type of fractures recorded at the time of the interview can be consulted in Table 1.

The presence of other comorbidities, such as thyroid pathologies (34.13%), diabetes (10.64%), chronic inflammatory diseases of the intestine (16.46%), celiac disease (2.03%), and rheumatoid arthritis (36.74%), was also evaluated.

Concerning lifestyle and habits, 47.37% of the sample declared that they neither smoked nor used alcohol (93.66%). Physical activity was performed by 61.57% of the patients, and most (81%) of the women spent at least 10 minutes per day outdoors on sunny days.

In terms of medication, 51.09% of the patients were being treated for osteoporosis; specifically, 74.78% took teriparatide, 22.22% took bisphosphonates, 2.13% took denosumab, and 2.99% took strontium ranelate. Of the 51.09% of the sample taking medications, 83.76% were using vitamin D and calcium supplements. All the patients' characteristics are reported in Table 1.

The QoLOS-NVFX IT analysis is reported in Table 2. All the items had a score below 2, from a minimum of 1.32 for IT 9 (lift a heavy object and carry it for at least 10 m) to a maximum of 1.87 for IT 22 (downhearted).



### *Psychometric validation*

Figure 1 shows the scree plot of the eigenvalues resulting from the EFA, suggesting the extraction of a single dimension. As can be observed in Table 3, all the factor loadings were high, ranging from .80 (IT 23) to .99 (IT 12). The fit indices of this model were satisfactory [ $\chi^2$  ( $df = 230, N = 195$ ) = 552.551,  $p < .001$ , RMSEA = .085 (90% CI .076–.094), CFI = .991, TLI = .990]. The overall NSC for this model was .98, suggesting high reliability.

The single-factor model resulting from the EFA was replicated on the calibration sample with the CFA, yielding a satisfactory overall fit for the fit indices, with the exception of RMSEA, which was  $> .08$ , and a test of close fit that was statistically significant [ $\chi^2$  ( $df = 230, N = 263$ ) = 905.75,  $p < .001$ , RMSEA = .106 (90% CI .076–.094), CFI = .953, TLI = .949]. Relying on these considerations, we created six parcels by generating five composites of four items and one composite of three items, balancing them for the total corrected item–total correlations (Little, Rhemtulla, Gibson, & Schoemann, 2013). The new CFA posited the same single latent dimension as above with the six parcels as observed indicators. Since the skewness and kurtosis of the parcels were not problematic (Tabachnick, B.G. & Fidell, 2013), this model was tested with maximum likelihood (ML) estimators (Muthén, L. K., & Muthén, n.d.) that fitted with the data very well [ $\chi^2$  ( $df = 9, N = 263$ ) = 11.78,  $p < .001$ , RMSEA = .034 (90% CI .00–.082), CFI = .998, TLI = .997]. A diagrammatic representation of this model is depicted in Figure 2, along with completely standardized estimates of factor loadings and residual variances. The reliability of the confirmation sample resulted in the following indices: Cronbach's  $\alpha = .94$ , MR = .96, CR = .96, AVE = .70.

Finally, the overall total score of the QoLOS-NVFX was correlated in both samples with the general health status indicator illustrated in previous sections. Since the total QoLOS-NVFX score was continuous and the general health status indicator had three ordered categories for the answer format, polyserial correlations were used. In both cases, this correlation was high (validation sample:  $r = .88$ ,  $p < .001$ ; calibration sample:  $r = .78$ ,  $p < .001$ ), supporting the convergent validity of the QoLOS-NVFX.

### **Discussion**

The present study was performed for developing and testing the psychometric properties of a new self-reported scale to measure QoL among postmenopausal osteoporotic women who had experienced fragility fractures other than vertebral ones, namely the Quality of Life Osteoporosis Scale—Non-vertebral Fractures (QoLOS-NVFX). The focal point of the QoLOS-NVFX is its unidimensional measure of ADL, with high reliability and high validity for assessing QoL in this specific population. The construct validity of the QoLOS-NVFX was supported with EFA and CFA;

1 the EFA strongly indicated that one single factor was satisfactory for explaining most of the variance  
2 of the data, and this was supported by the CFA and other fit indices. After this first deep understanding  
3 of the nature and dimensionality of the scale, for a better fitting solution and to minimize potential  
4 pitfalls, the parceling technique was employed. Specifically, six parcels were created that included  
5 five composites of four items and one composite of three items with good factor loadings ranging  
6 from .922 to .895 (Figure 2).  
7  
8  
9

10 The derived unidimensionality of the QoLOS-NVFX seems to be in contrast with other QoL  
11 tools that outline the multidimensionality of the construct (de la Loge et al., 2005; Marquis et al.,  
12 2001). It is known that items on a scale are the manifestations of latent variables, and the differences  
13 observed in the answers are considered to represent the differences on the latent construct. Given that  
14 the items on the scale derive from the construct intended to be measured, the unidimensionality of  
15 QoLOS-NVFX is probably related to its tailored items, which were specifically developed to be used  
16 by a well-defined population. Furthermore, the QoLOS-NVFX has demonstrated good psychometric  
17 criteria for reliability, as patients with osteoporosis without VFX were asked about their ability to  
18 perform their ADL.  
19  
20  
21  
22  
23  
24  
25  
26

27 The QoLOS-NVFX score ranged from 23 to 69, with a mean of 35.66. Especially, most  
28 patients answered “insufficient” for items IT 1, IT 2, IT 5, IT 7, IT 8, IT 9, IT 14, IT 16, IT 17, and  
29 IT18; “good” for items IT 3, IT 4, IT 6, IT 15, IT 19, and IT 20; and “sometimes” for items IT 21, IT  
30 22, and IT 23. Responses of “excellent” or “never” were provided by an extremely small percentage  
31 of women compared with the three types of answers stated above probably due to the recent fracture.  
32  
33  
34  
35

36 The women’s general state of health exhibited an average of 1.5, maintaining the majority  
37 values attributed to QoLOS-NVFX, which tended to be “insufficient” for most of the items. In  
38 addition, the responses given to the single items on the scale were compared with the type of fracture  
39 suffered by the women, and it was seen that those who had suffered fractures in the upper limbs had  
40 better QoLs than those who had suffered fractures of the lower limbs, which was presumably more  
41 disabling. To our knowledge, no previous studies have developed a specific instrument for measuring  
42 QoL in postmenopausal osteoporotic women who suffer from minor fractures.  
43  
44  
45  
46  
47  
48  
49  
50  
51

## 52 **Limitations**

53  
54 Our study had several limitations. First, the content validity of the QoLOS-NVFX was  
55 established in a specific population, consisting of postmenopausal women enrolled in outpatient  
56 clinics of various health institutions in Italy, with a history of at least one previous fracture other than  
57 a vertebral one and no presence of severe renal failure or pre-existing/ongoing neoplastic diseases.  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 Therefore, validity may not necessarily be assumed for all patients. Nevertheless, the strength of our  
3 study was that we validated our tool in the population in which the instrument was to be used and  
4 further validation study in other osteoporosis populations, such as men or women that are not in  
5 postmenopause, would be required to confirm the strong psychometric properties of this scale.  
6

7  
8 Second, we considered only the answers given to the questions at T0, and given that the study  
9 had a longer effective duration of 6 months, it would be interesting to investigate how the QoL  
10 changed over time by measuring the same item at various follow-up visits. Then, we would be able  
11 to deduce whether it is normal to have a QoL at T0 that reaches the worst level directly after the  
12 traumatic event.  
13  
14

15  
16 Thirdly, we used a 3-point Likert scale that may have increased the possibility of losing some  
17 valuable information. Therefore, it would be appropriate to conduct a study that takes into account  
18 responses on a 5-point Likert scale to better discriminate the concept and to enhance the accuracy of  
19 participants' responses.  
20  
21  
22

## 23 24 **Conclusion**

25  
26 In summary, the tool developed in this study was found to be a potentially useful measure that  
27 is reliable and valid for evaluating QoL in postmenopausal osteoporotic women after fragility  
28 fractures other than VFX to help patients and clinicians in clinical practice. The construct validity  
29 was supported with adequate EFA and CFA results, while the model fit and reliability were supported  
30 by the four NSC indices. To enable the QoLOS-NVFX to be used worldwide, further studies should  
31 be carried out to validate other versions of the instrument.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## REFERENCES

- 1  
2 Arbuckle, J. (1996). *Full information estimation in the presence of incomplete data*. (Advanced  
3 Structural Equation Modeling, Ed.) (IN GA Marc). Retrieved from  
4 [https://scholar.google.com/scholar?cluster=8156515034596837149&hl=en&as\\_sdt=2005&sciodt=0,5](https://scholar.google.com/scholar?cluster=8156515034596837149&hl=en&as_sdt=2005&sciodt=0,5)  
5  
6
- 7 Badia, X., Díez-Pérez, A., Alvarez-Sanz, C., Díaz-López, B., Diaz-Curiel, M., Guillén, F., ... Spanish  
8 GRECO Study Group. (2001). Measuring quality of life in women with vertebral fractures due  
9 to osteoporosis: a comparison of the OQLQ and QUALEFFO. *Quality of Life Research: An*  
10 *International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation*, 10(4),  
11 307–17. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11763244>  
12  
13
- 14 Badia, X., Díez-Pérez, A., Lahoz, R., Lizán, L., Nogués, X., & Iborra, J. (2004). The ECOS-16  
15 questionnaire for the evaluation of health related quality of life in post-menopausal women with  
16 osteoporosis. *Health and Quality of Life Outcomes*, 2(1), 41. [https://doi.org/10.1186/1477-7525-](https://doi.org/10.1186/1477-7525-2-41)  
17 2-41  
18
- 19 Bentler, P. M. (1990). Comparative fit indexes in structural models. *Psychological Bulletin*, 107(2),  
20 238–46. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/2320703>  
21
- 22 Bianchi, M. L., Orsini, M. R., Saraifoger, S., Ortolani, S., Radaelli, G., & Betti, S. (2005). Quality of  
23 life in post-menopausal osteoporosis. *Health and Quality of Life Outcomes*, 3(1), 78.  
24 <https://doi.org/10.1186/1477-7525-3-78>  
25
- 26 *Broken Bones, Broken Lives*. (n.d.). Retrieved from [http://share.iofbonehealth.org/EU-6-](http://share.iofbonehealth.org/EU-6-Material/Reports/IOF_Report_EU.pdf)  
27 Material/Reports/IOF Report\_EU.pdf  
28
- 29 Brown, T. A. (2015). *Confirmatory Factor Analysis for Applied Research*. (Guilford Publications,  
30 Ed.) (2nd ed.). New York. Retrieved from  
31 [https://books.google.it/books?hl=it&lr=&id=JDb3BQAAQBAJ&oi=fnd&pg=PP1&dq=Brown](https://books.google.it/books?hl=it&lr=&id=JDb3BQAAQBAJ&oi=fnd&pg=PP1&dq=Brown,+T.+A.+(2015).+Confirmatory+factor+analysis+for+applied+research+(2nd+Edition).+New+York:+Guilford+Publications&ots=-0Ezf-bC1c&sig=IH53UPCmVBxNkGZ1w2C0b9Dtcl#v=onepage&q&f=fal)  
32 [,+T.+A.+\(2015\).+Confirmatory+factor+analysis+for+applied+research+\(2nd+Edition\).+New+](https://books.google.it/books?hl=it&lr=&id=JDb3BQAAQBAJ&oi=fnd&pg=PP1&dq=Brown,+T.+A.+(2015).+Confirmatory+factor+analysis+for+applied+research+(2nd+Edition).+New+York:+Guilford+Publications&ots=-0Ezf-bC1c&sig=IH53UPCmVBxNkGZ1w2C0b9Dtcl#v=onepage&q&f=fal)  
33 [York:+Guilford+Publications&ots=-0Ezf-](https://books.google.it/books?hl=it&lr=&id=JDb3BQAAQBAJ&oi=fnd&pg=PP1&dq=Brown,+T.+A.+(2015).+Confirmatory+factor+analysis+for+applied+research+(2nd+Edition).+New+York:+Guilford+Publications&ots=-0Ezf-bC1c&sig=IH53UPCmVBxNkGZ1w2C0b9Dtcl#v=onepage&q&f=fal)  
34 [bC1c&sig=IH53UPCmVBxNkGZ1w2C0b9Dtcl#v=onepage&q&f=fal](https://books.google.it/books?hl=it&lr=&id=JDb3BQAAQBAJ&oi=fnd&pg=PP1&dq=Brown,+T.+A.+(2015).+Confirmatory+factor+analysis+for+applied+research+(2nd+Edition).+New+York:+Guilford+Publications&ots=-0Ezf-bC1c&sig=IH53UPCmVBxNkGZ1w2C0b9Dtcl#v=onepage&q&f=fal)  
35  
36
- 37 Byrne, B. M. (2012). *Structural equation modeling with Mplus: basic concepts, applications, and*  
38 *programming*. Routledge. Retrieved from  
39 [https://books.google.it/books?hl=it&lr=&id=8vHqQH5VxBIC&oi=fnd&pg=PR5&dq=Byrne,](https://books.google.it/books?hl=it&lr=&id=8vHqQH5VxBIC&oi=fnd&pg=PR5&dq=Byrne,+B.+(2011).+Structural+equation+modeling+with+Mplus:+Basic+concepts,+applications,+and+programming.+New+York,+NY:+Routledge.&ots=yM8PRuCDQb&sig=DV5VupuHgD1kYSmiqzs--I3MD1Q#v=on)  
40 [+B.+\(2011\).+Structural+equation+modeling+with+Mplus:+Basic+concepts,+applications,+an](https://books.google.it/books?hl=it&lr=&id=8vHqQH5VxBIC&oi=fnd&pg=PR5&dq=Byrne,+B.+(2011).+Structural+equation+modeling+with+Mplus:+Basic+concepts,+applications,+and+programming.+New+York,+NY:+Routledge.&ots=yM8PRuCDQb&sig=DV5VupuHgD1kYSmiqzs--I3MD1Q#v=on)  
41 [d+programming.+New+York,+NY:+Routledge.&ots=yM8PRuCDQb&sig=DV5VupuHgD1k](https://books.google.it/books?hl=it&lr=&id=8vHqQH5VxBIC&oi=fnd&pg=PR5&dq=Byrne,+B.+(2011).+Structural+equation+modeling+with+Mplus:+Basic+concepts,+applications,+and+programming.+New+York,+NY:+Routledge.&ots=yM8PRuCDQb&sig=DV5VupuHgD1kYSmiqzs--I3MD1Q#v=on)  
42 [YSmiqzs--I3MD1Q#v=on](https://books.google.it/books?hl=it&lr=&id=8vHqQH5VxBIC&oi=fnd&pg=PR5&dq=Byrne,+B.+(2011).+Structural+equation+modeling+with+Mplus:+Basic+concepts,+applications,+and+programming.+New+York,+NY:+Routledge.&ots=yM8PRuCDQb&sig=DV5VupuHgD1kYSmiqzs--I3MD1Q#v=on)  
43  
44
- 45 Cantarelli, F. B., Szejnfeld, V. L., Oliveira, L. M., Ciconelli, R. M., & Ferraz, M. B. (n.d.). Quality  
46 of life in patients with osteoporosis fractures: cultural adaptation, reliability and validity of the  
47 Osteoporosis Assessment Questionnaire. *Clinical and Experimental Rheumatology*, 17(5), 547–  
48 51. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10544837>  
49
- 50 Cook, D. J., Guyatt, G. H., Adachi, J. D., Epstein, R. S., Juniper, E. F., Austin, P. A., ... Ioannidis,  
51 G. (1999). Development and validation of the mini-osteoporosis quality of life questionnaire  
52 (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality  
53 of Life Study Group. *Osteoporosis International: A Journal Established as Result of*  
54 *Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis*  
55 *Foundation of the USA*, 10(3), 207–13. <https://doi.org/10.1007/s001980050217>  
56  
57
- 58 de la Loge, C., Sullivan, K., Pinkney, R., Marquis, P., Roux, C., & Meunier, P. (2005). Cross-cultural  
59 validation and analysis of responsiveness of the QUALIOST: QUALity of Life questionnaire In  
60 OSTeoporosis. *Health and Quality of Life Outcomes*, 3(1), 69. <https://doi.org/10.1186/1477->  
61  
62  
63  
64  
65

- 1  
2 Edelmuth, S. V. C. L., Sorio, G. N., Sprovieri, F. A. A., Gali, J. C., & Peron, S. F. (2018).  
3 Comorbidities, clinical interurrences, and factors associated with mortality in elderly patients  
4 admitted for a hip fracture. *Revista Brasileira de Ortopedia*, 53(5), 543–551.  
5 <https://doi.org/10.1016/j.rboe.2018.07.014>  
6
- 7 González Matarín, P. J., Martínez-Amat, A., Lomas-Vega, R., de Guevara, N. M. L., Díaz-Mohedo,  
8 E., Martínez López, E., ... Hita-Contreras, F. (2014). Validation of the Quality of Life  
9 Questionnaire of the European Foundation for Osteoporosis-31 in Spanish postmenopausal  
10 women. *Menopause*, 21(5), 469–476. <https://doi.org/10.1097/GME.0b013e3182a6cc64>  
11
- 12 Green, S. B., & Yang, Y. (2009). Commentary on Coefficient Alpha: A Cautionary Tale.  
13 *Psychometrika*, 74(1), 121–135. <https://doi.org/10.1007/s11336-008-9098-4>  
14
- 15 Helmes, E., Hodsmán, A., Lazowski, D., Bhardwaj, A., Crilly, R., Nichol, P., ... Pederson, L. (1995).  
16 A questionnaire to evaluate disability in osteoporotic patients with vertebral compression  
17 fractures. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*,  
18 50(2), M91-8. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/7874595>  
19
- 20 Hepguler, S., Atamaz, F. C., Pinar, Y., & Ozturk, C. (2013). Acceptability, validity and reliability of  
21 the Turkish QUALIOST(®) in postmenopausal women with osteoporosis. *Rheumatology*  
22 *International*, 33(3), 757–61. <https://doi.org/10.1007/s00296-012-2443-z>  
23
- 24 Hernlund, E., Svedbom, A., Ivergård, M., Compston, J., Cooper, C., Stenmark, J., ... Kanis, J. A.  
25 (2013). Osteoporosis in the European Union: medical management, epidemiology and economic  
26 burden. *Archives of Osteoporosis*, 8(1–2), 136. <https://doi.org/10.1007/s11657-013-0136-1>  
27
- 28 Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indexes in covariance structure analysis:  
29 Conventional criteria versus new alternatives. *Structural Equation Modeling: A*  
30 *Multidisciplinary Journal*, 6(1), 1–55. <https://doi.org/10.1080/10705519909540118>  
31
- 32 IBM. (2013). Corporate Responsibility Report. Retrieved from [https://www-  
33 31.ibm.com/ibm/cn/corporateresponsibility/download/2013\\_report\\_en.pdf](https://www-31.ibm.com/ibm/cn/corporateresponsibility/download/2013_report_en.pdf)  
34
- 35 Jenkinson, C., Coulter, A., & Wright, L. (1993). Short form 36 (SF36) health survey questionnaire:  
36 normative data for adults of working age. *BMJ (Clinical Research Ed.)*, 306(6890), 1437–40.  
37 <https://doi.org/10.1136/bmj.306.6890.1437>  
38
- 39 Lin, X., Xiong, D., Peng, Y.-Q., Sheng, Z.-F., Wu, X.-Y., Wu, X.-P., ... Liao, E.-Y. (2015).  
40 Epidemiology and management of osteoporosis in the People's Republic of China: current  
41 perspectives. *Clinical Interventions in Aging*, 10, 1017–33. <https://doi.org/10.2147/CIA.S54613>  
42
- 43 Lips, P., Agnusdei, D., Caulin, F., Cooper, C., Johnell, O., Kanis, J., ... Wiklund, I. (1996). The  
44 development of a European questionnaire for quality of life in patients with vertebral  
45 osteoporosis. *Scandinavian Journal of Rheumatology. Supplement*, 103, 84-5; discussion 86-8.  
46 Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/8966496>  
47
- 48 Lips, P., Jameson, K., Bianchi, M. L., Goemaere, S., Boonen, S., Reeve, J., ... Working Group for  
49 Quality of Life of the International Osteoporosis Foundation. (2010). Validation of the IOF  
50 quality of life questionnaire for patients with wrist fracture. *Osteoporosis International: A*  
51 *Journal Established as Result of Cooperation between the European Foundation for*  
52 *Osteoporosis and the National Osteoporosis Foundation of the USA*, 21(1), 61–70.  
53 <https://doi.org/10.1007/s00198-009-0946-6>  
54
- 55 Little, T. D., Rhemtulla, M., Gibson, K., & Schoemann, A. M. (2013). Why the items versus parcels  
56 controversy needn't be one. *Psychological Methods*, 18(3), 285–300.  
57 <https://doi.org/10.1037/a0033266>  
58

- 1 Madureira, M. M., Ciconelli, R. M., & Pereira, R. M. R. (2012). Quality of life measurements in  
2 patients with osteoporosis and fractures. *Clinics (Sao Paulo, Brazil)*, 67(11), 1315–20. Retrieved  
3 from <http://www.ncbi.nlm.nih.gov/pubmed/23184210>
- 4 Marquis, P., Cialdella, P., & De la Loge, C. (2001). Development and validation of a specific quality  
5 of life module in post-menopausal women with osteoporosis: the QUALIOST. *Quality of Life*  
6 *Research: An International Journal of Quality of Life Aspects of Treatment, Care and*  
7 *Rehabilitation*, 10(6), 555–66. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11789555>
- 9 Muthén, L. K., & Muthén, B. O. (n.d.). *Mplus User's Guide: Statistical Analysis with Latent*  
10 *Variables (1998-2012)*. (Muthén & Muthén, Ed.) (7th ed.). Los Angeles.
- 12 Nunnally, J. C. and Bernstein, I. H. (1994). *Psychometric theory*. (I. McGraw-Hill, Ed.) (3rd ed.).  
13 New York.
- 15 Panula, J., Pihlajamäki, H., Mattila, V. M., Jaatinen, P., Vahlberg, T., Aarnio, P., & Kivelä, S.-L.  
16 (2011). Mortality and cause of death in hip fracture patients aged 65 or older: a population-based  
17 study. *BMC Musculoskeletal Disorders*, 12, 105. <https://doi.org/10.1186/1471-2474-12-105>
- 19 Pisani, P., Renna, M. D., Conversano, F., Casciaro, E., Di Paola, M., Quarta, E., ... Casciaro, S.  
20 (2016). Major osteoporotic fragility fractures: Risk factor updates and societal impact. *World*  
21 *Journal of Orthopedics*, 7(3), 171–81. <https://doi.org/10.5312/wjo.v7.i3.171>
- 23 Randell, A. G., Bhalerao, N., Nguyen, T. V, Sambrook, P. N., Eisman, J. A., & Silverman, S. L.  
24 (1998). Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis  
25 Assessment Questionnaire. *The Journal of Rheumatology*, 25(6), 1171–9. Retrieved from  
26 <http://www.ncbi.nlm.nih.gov/pubmed/9632082>
- 29 Silverman, S. L. (2000). The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid  
30 disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis. *Quality of*  
31 *Life Research*, 9(6suppl), 767–774. <https://doi.org/10.1023/A:1008934208764>
- 33 Steiger, J. H. (1990). Structural Model Evaluation and Modification: An Interval Estimation  
34 Approach. *Multivariate Behavioral Research*, 25(2), 173–180.  
35 [https://doi.org/10.1207/s15327906mbr2502\\_4](https://doi.org/10.1207/s15327906mbr2502_4)
- 37 Tabachnick, B.G. & Fidell, L. S. (2013). *Using Multivariate Statistics*. (Pearson Education, Ed.).  
38 Boston. Retrieved from  
39 [https://books.google.it/books/about/Using\\_Multivariate\\_Statistics.html?id=ucj1ygAACAAJ&redir\\_esc=y](https://books.google.it/books/about/Using_Multivariate_Statistics.html?id=ucj1ygAACAAJ&redir_esc=y)
- 42 The World Health Organization Quality of Life assessment (WHOQOL): position paper from the  
43 World Health Organization. (1995). *Social Science & Medicine (1982)*, 41(10), 1403–9.  
44 Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/8560308>
- 47 Tsuda, T. (2017). Epidemiology of fragility fractures and fall prevention in the elderly: a systematic  
48 review of the literature. *Current Orthopaedic Practice*, 28(6), 580–585.  
49 <https://doi.org/10.1097/BCO.0000000000000563>
- 51 Tucker, L. R., & Lewis, C. (1973). A reliability coefficient for maximum likelihood factor analysis.  
52 *Psychometrika*, 38(1), 1–10. <https://doi.org/10.1007/BF02291170>
- 54 van Schoor, N. M., Knol, D. L., Glas, C. A. W., Ostelo, R. W. J. G., Leplège, A., Cooper, C., ... Lips,  
55 P. (2006). Development of the Qualeffo-31, an osteoporosis-specific quality-of-life  
56 questionnaire. *Osteoporosis International: A Journal Established as Result of Cooperation*  
57 *between the European Foundation for Osteoporosis and the National Osteoporosis Foundation*  
58 *of the USA*, 17(4), 543–51. <https://doi.org/10.1007/s00198-005-0024-7>
- 61 Wilson, S., Sharp, C. A., & Davie, M. W. J. (2012). Health-related quality of life in patients with

osteoporosis in the absence of vertebral fracture: a systematic review. *Osteoporosis International*, 23(12), 2749–2768. <https://doi.org/10.1007/s00198-012-2050-6>

Yilmaz, F., Doğu, B., Sahin, F., Sirzai, H., & Kuran, B. (2014). Investigation of responsiveness indices of generic and specific measures of health related quality of life in patients with osteoporosis. *Journal of Back and Musculoskeletal Rehabilitation*, 27(4), 391–7. <https://doi.org/10.3233/BMR-140459>




Figure 1. Scree plot of eigenvalues for the calibration (EFA) sample.






Figure 2. Estimates of the CFA model fitted with parcels on the validation sample. F = Latent variable; P1–P6 = Parcels. Factor loadings and residual variances are presented in a completely standardized solution.

Table 1. Characteristics of the Sample ( $N = 458$ )

AGE (mean, SD)	75 (10.12)		
		<i>N</i>	%
EDUCATION	None	87	18.55
	Elementary school	154	34.06
	Junior high school	123	27.07
	High school	79	18.77
	Degree	7	1.55
EMPLOYMENT	Employed	92	20.09
	Unemployed	352	76.85
	Other	14	3.06
BMI	Underweight	46	10.05
	Normal weight	194	42.35
	Overweight/Pre-obesity	152	33.19
	Class I Obesity	49	10.69
	Class II Obesity	14	3.06
Class III Obesity	3	0.66	
Menopause occurrence (mean, SD)	48.56 (5.00)		
Menopause type	Spontaneous	391	85.37
	Induced	67	14.63
FRACTURE	Previous fracture	148	32.31
	Arm/shoulder	69	46.63
	Femur	26	17.56
	Leg/foot	20	13.52
	Other	33	22.29
	Current fracture	329	71.83
	Arm/shoulder	77	23.42
	Femur	193	58.66
	Leg/foot	48	14.58
	Other	11	3.34
	Current fracture with previous experience	172	48.45
Trivial trauma	285	80.28	
LIFESTYLE	Smoking	217	47.37
	Alcohol	429	93.66
	Physical activity	282	61.57
	Outdoors during sunny day	371	81
COMORBIDITY	Thyroid diseases	170	34.13
	Diabetes	53	10.64
	Chronic inflammatory diseases of the intestine	82	16.46
	Celiac disease	10	2.03
	Rheumatoid arthritis	183	36.74
PHARMACOTHERAPY	Medication use	234	51.09
	<u>Type of medication</u>		
	Teriparatide	175	74.78
	Bisphosphonate	52	22.22
	Denosumab	5	2.13
	Strontium ranelate	7	2.99
	Vitamin D	196	83.76
Calcium	196	83.76	

Table 2. Item Descriptive Analysis of the QoLOS-NVFX (N = 458)

How do you currently evaluate your ability to ...?	Mean (SD)	Excellent %	Good %	Insufficient %
IT 1. Dress	1.59 (0.61)	7.01	45.95	47.04
IT 2. Take a bath or shower	1.52 (0.56)	3.72	44.85	51.43
IT 3. Sit down and using the toilet	1.62 (0.57)	4.82	52.95	42.23
IT 4. Rest at night	1.65 (0.57)	5.25	54.92	39.83
IT 5. Clean the house	1.39 (0.57)	1.98	35.24	62.78
IT 6. Prepare meals	1.56 (0.52)	3.09	50.01	46.90
IT 7. Do shopping	1.42 (0.55)	2.66	37.03	60.31
IT 8. Wash dishes	1.51 (0.55)	3.32	44.92	51.76
IT 9. Lift a heavy object and carry it for at least 10 m	1.32 (0.56)	2.21	27.87	69.92
IT 10. Stand up from a chair	1.52 (0.51)	4.82	42.67	52.51
IT 11. Bend at the trunk	1.39 (0.58)	2.86	34.21	62.93
IT 12. Kneel	1.36 (0.54)	2.42	32.09	65.49
IT 13. Climb a staircase	1.51 (0.53)	3.08	44.94	51.98
IT 14. Walk 100 m	1.54 (0.55)	4.01	46.44	49.55
IT 15. Go outside the house during the week	1.60 (0.57)	4.03	52.34	43.63
IT 16. Use public transport	1.47 (0.56)	2.51	42.72	54.77
IT 17. Garden, look after an animal, etc	1.48 (0.54)	2.74	43.24	54.02
IT 18. Perform any hobby	1.51 (0.55)	2.72	45.92	51.36
IT 19. Visit a cinema, theatre	1.54 (0.55)	2.29	50.01	47.70
IT 20. Visit friends or relatives	1.60 (0.54)	3.38	53.95	42.67
Do you have a tendency to feel ...?		Never %	Sometimes%	Every day %
IT 21. Tired	1.64 (0.54)	6.69	50.67	42.64
IT 22. Downhearted	1.87 (0.55)	11.34	64.54	24.12
IT 23. Lonely	1.86 (0.60)	10.86	64.02	25.12

*Table 3.* Factor Loadings of the EFA conducted on the Calibration Sample ( $n = 195$ )

Items	Factor Loadings
IT 1. Dressing	.89
IT 2. Taking a bath or shower	.94
IT 3. Sitting down and using the toilet	.90
IT 4. Resting at night	.85
IT 5. Cleaning the house	.96
IT 6. Preparing meals	.97
IT 7. Doing shopping	.95
IT 8. Washing dishes	.93
IT 9. Lifting a heavy object and carrying it for at least 10 m	.94
IT 10. Standing up from a chair	.92
IT 11. Bending at the trunk	.94
IT 12. Kneeling	.99
IT 13. Climbing a staircase	.94
IT 14. Walking 100 m	.96
IT 15. Going outside the house during the week	.91
IT 16. Using public transport	.98
IT 17. Gardening, looking after an animal, etc	.97
IT 18. Performing any hobby	.96
IT 19. Visiting a cinema, theatre	.97
IT 20. Visiting friends or relatives	.94
IT 21. Tendency to feel tired	.85
IT 22. Tendency to feel downhearted	.82
IT 23. Tendency to feel lonely	.80